Amgen, Inc.

Motley Fool contributors recommend AbbVie, Amgen, and Pfizer as top dividend stocks for October, highlighting their strong dividend histories, yields, and business strengths.

Regeneron Pharmaceuticals faces headwinds with Eylea, its key eye disease treatment, due to biosimilar competition and a recent court decision favoring Amgen. Despite this, Regeneron's higher-dose Eylea and growth driver Dupixent, an eczema treatment, suggest resilience. Long-term biotech investors are advised to consider buying Regeneron shares on the dip.

Pharmaceutical companies are conducting clinical trials in Brazil and Turkey due to lower costs. Regulatory reforms by TITCK and ANVISA streamline approval processes, attracting major firms like AstraZeneca and Merck. Phase 3 trials for cancer drugs like Aflibercept and Savolitinib are underway. Collaboration with local institutions and CROs enhances trial quality and efficiency, positioning these countries as key clinical research hubs.

Oncolytic virus immunotherapy, a groundbreaking cancer treatment, targets cancer cells while sparing healthy ones, offering a safer and effective alternative to conventional therapies. Advances like Oncorine, Imlygic, and Delytact highlight its potential, promising a tailored, multifaceted approach to cancer treatment.

Erik Schrage, Director of Global Clinical Supply Chain and leader of the Ability Bettered Through Leadership and Education group in Breda, shares his experience as a caregiver to his son with a disability and his commitment to creating an inclusive workplace.

The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.

Blue Shield of California cuts Humira cost to $525/dose by bypassing PBMs, offering biosimilar at $0 co-pay from Jan 2025. This model aims to maximize consumer benefits over profit, with potential expansion to other drugs.

New companies aim to challenge Eli Lilly and Novo Nordisk's dominance in the GLP-1 weight-loss drug market, projected to reach $200 billion by 2031. Emerging competitors like Roche, Amgen, Pfizer, and AstraZeneca focus on enhanced efficacy and convenience to disrupt the market. By 2029, 16 new drugs are expected to enter the market, adding $70 billion to the segment. Despite pricing challenges and limited international penetration, GLP-1 drugs are expected to see significant usage in the U.S., with Novo and Lilly maintaining a strong market presence through pipeline advancements.

Pharma companies like Novo Nordisk, Viking Therapeutics, Amgen, and CRISPR Therapeutics are set to announce clinical trial results for next-gen weight loss drugs and a cancer/autoimmune disease cell therapy. Moderna may also launch a new product beyond its COVID-19 vaccine.

Cassava Sciences misled investors with falsified Alzheimer’s drug data; FDA action needed. Major biotech events this quarter include Amgen, Novo Nordisk, and AbbVie drug readouts. Triveni Bio raises $115 million for immunology treatments. Eli Lilly considers obesity drug testing for prevention, similar to Novo Nordisk. Lilly invests $4.5 billion in a research and manufacturing hub.